GLCCI1 is a novel protector against glucocorticoid-induced apoptosis in T cells

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• Glucocorticoids (GCs) induce T-cell apoptosis via the GC receptor (GR), crucial for controlling lymphocyte function.
• The precise downstream molecular pathways mediating GC-induced T-cell apoptosis remain incompletely understood.
• Identifying novel mediators is essential for understanding lymphocyte regulation and developing targeted therapies.

Purpose of the Study:

• To identify novel downstream molecules in the GC-GR signaling cascade.
• To investigate the role of GC-induced transcript 1 (GLCCI1) in T-cell apoptosis.
• To elucidate the molecular mechanism by which GLCCI1 modulates T-cell apoptosis.

Main Methods:

• Transfection of human embryonic kidney QBI293A cells with GLCCI1.
• GC treatment of a cultured thymocyte cell line.
• Gene knockdown of GLCCI1 in thymocytes.
• Generation and analysis of transgenic mice overexpressing human GLCCI1.
• Co-immunoprecipitation and Western blot analysis to study protein interactions and phosphorylation.

Main Results:

• GLCCI1 was identified as a novel downstream molecule of the GC-GR cascade.
• GLCCI1 acts as an antiapoptotic mediator in thymic T cells.
• GLCCI1 binds to dynein light chain LC8 and inhibits PAK1 kinase activity, reducing LC8 phosphorylation and Bim expression.
• Overexpression of GLCCI1 in mice led to enlarged thymi with increased thymocyte numbers.

Conclusions:

• GLCCI1 is a novel antiapoptotic mediator in thymic T cells, protecting against GC-induced apoptosis.
• GLCCI1 functions by inhibiting the proapoptotic kinase activity of PAK1 towards LC8.
• GLCCI1 represents a potential target for regulating T-cell apoptosis in clinical settings.